Table 3.

Baseline characteristics of clinical and radiologic measures

MSH6-positive (n = 11), median (range)MSH6-negative (n = 9), median (range)P
Age at recurrence, y49 (23-70)56 (31-67)NS
Gender (% male)6478
Calculated pretreatment tumor volume, cc11.79 (1.65-46.59)5.12 (0-53.73)NS
Pretreatment T1-post-gadolinium enhancement volume, cc12.6 (1.8-54.85)9.75 (0-53.73)NS
Pretreatment T1 enhancement volume (i.e., pre-gadolinium), cc1.37 (0-41.06)0 (0-11.33)NS
Pretreatment FLAIR volume, cc43.16 (5-178.4)52.75 (8.29-229.6)NS
Recurrence T1-post-gadolinium enhancement volume, cc9.15 (5.2-44.1)16.17 (4.19-82.83)NS
Recurrence FLAIR volume, cc56.13 (8.05-185.3)57.53 (10.92-353.2)NS
Time elapsed between initial and recurrence scans, d170 (71-364)153 (57-432)NS
Rate of FLAIR change, cc/d0.009 (−0.645-0.406)0.060 (−0.221-1.258)NS
Rate of T1-post-gadolinium enhancement change, cc/d0.001 (−0.087-0.068)0.106 (−0.055-0.288)0.020
  • NOTE: Radiologic assessment factors were compared between the two groups of patients with glioblastoma recurrences determined by MSH6-positive or MSH6-negative immunohistochemical staining. No significant differences were noted between potential confounding measures. Tumor growth rate, as assessed by rate of T1-post-gadolinium enhancement change, was higher in the MSH6-negative group.

    Abbreviation: NS, not significant (P > 0.025).